NEW YORK (GenomeWeb News) - Invitrogen said today that it has signed an exclusive agreement with software developer Brendan Technologies to integrate the company’s StatLIA assay analysis software with its protein analysis tools.
Invitrogen said that the StatLIA software will be designed to work with protein quantitation via mass spectrometry, a technology platform that the company will add to its offerings when its planned acquisition of Applied Biosystems closes in the fall.
"This software maximizes the value of our reagents through state-of-the-art computations and analysis of proteomics mass spectrometry," said Kip Miller, Invitrogen's senior vice president of BioDiscovery, in a statement. "With the pending combination with Applied Biosystems, we will now have greater access to the mass spectrometry customers, allowing us to provide even more solutions addressing their needs."
Financial terms of the agreement were not disclosed.